Shares of MicroVision sank after the lidar maker's October 7 business update delivered exactly what investors feared: a status quo outlook at a moment when they needed proof that revenue was accelerating. The stock slid 9.2% in after-hours trading after management reaffirmed full-year 2026 revenue guidance of $10 million to $15 million without any upward revision, sending shares to $1.38.
The broader market was essentially flat on the day, underscoring that this was entirely a company-specific disappointment.
• A Tiny Revenue Base Makes Every Guidance Tweak High-Stakes. Second-quarter 2026 revenue stood at roughly $1.47 million against a net loss of approximately $36.9 million, with operating cash outflow of around $19.15 million.
The majority of the $10–$15 million full-year target is back-loaded into the second half, meaning MicroVision needs a steep ramp in Q3 and Q4 just to hit the low end. Missing the window to raise guidance signals that ramp hasn't materialized faster than plan.
• Cash Is Dwindling While Losses Stay Enormous. As of June 30, cash and equivalents had fallen to $27.2 million, down from $32.4 million at year-end 2025, while total debt stood at $45.5 million — putting net cash at negative $18.2 million.
Full-year cash usage guidance is roughly $60 million , which means the company will likely need to tap equity markets again — further diluting shareholders already battered by a 92.7% decline over the past year.
• The 2027 Doubling Promise Asks for a Leap of Faith. MicroVision projects revenue to double in 2027 across industrial, security, defense, and intelligent infrastructure markets.
Its Orlando facility and existing inventory can support that growth without major new capital spending, and the next phase of cost-cutting should produce meaningful savings. But doubling $10–$15 million still yields only $20–$30 million — modest for a company burning cash at ten times its revenue rate.
• The Stock Is Priced for Skepticism — and Rightly So. MicroVision's price-to-sales ratio sits at roughly 11x, far below its historical median of about 40x , and the stock is flirting with its all-time low of $1.40.
Market capitalization has shrunk to roughly $46 million — a fraction of the company's cumulative losses. Until MicroVision can demonstrate that its commercial pipeline is translating into materially higher revenue, the gap between its ambitious 2027 targets and its current financial reality will likely keep the stock under pressure.